

Initializing and Prioritizing Contact Investigations

Lori Eitelbach, BSN, RN October 31, 2023

TB Contact Investigation (Pilot)
October 31, 2023
San Antonio, Texas

1

Lori Eitelbach, BSN, RN has the following disclosures to make:

- No conflict of interests
- No relevant financial relationships with any commercial companies pertaining to this educational activity



Initiating and Prioritizing TB Contact Investigations

LORI EITELBACH, BSN, RN

TB PROGRAM MANAGER, WILLIAMSON COUNTY, TX

HEARTLAND NATIONAL TB CENTER, 10.31.23

3



OBJECTIVES

- Determine when a TB contact investigation should be initiated.
- Prioritize among contact investigations.
- Identify your patient's infectious period.

TB Statistics 2022

- •10M worldwide
- •8,300 in USA
- •Up to 13 million people in the United States living with LTBI
- •If not treated for LTBI, they are at risk for developing active TB disease
- •An average of 10 contacts are identified for each TB case
- Approximately 20-30% of all TB contacts are infected with LTBI
- Approximately 1% of all TB contacts have active TB disease

Every TB patient started as a TB contact

https://www.cdc.gov/tb/education/skillscourse/day1/d_link_text02.htm

5

Systematic Approach to TB Contact Investigation Collect and evaluate existing information about Index Case

nterview Index Case

Determine infectious period

Review information and develop plan for investigation

Prioritize contacts

Conduct and evaluate sites of transmission (field visits)

Conduct contact assessments (screening, testing)

Determine whether to expand or conclude investigation


Evaluate CI activities

These steps may not always be done in sequential order


When to Initiate a TB Contact Investigation

As soon as suspected* or confirmed infectious TB case comes to public health attention (state, regional or local health department [HD]).

*Assessment of priority contacts can begin before case is confirmed. If case is eventually confirmed, continue with full Cl. If person is found to NOT have infectious TB disease, stop Cl process.



7





When is a Contact Investigation Not Necessary?



- •LTBI
- Positive sputum smears, negative NAAT
 - Get 2 negative NAATs most likely Nontuberculosis Mycobacterium (NTM)
- Extrapulmonary TB
- Child under 10 years old
 - If case less than 5 years old, source case investigation should be initiated

9

Prioritizing Among Contact Investigations

If faced with multiple TB cases, health departments may have to decide which cases should be higher priority for conducting Cl's.

Decision will be influenced by:

- Likelihood of transmission (e.g., sputum smear positive*, cavity on chest x-ray, cough, and exposure environment)
- Risk of contacts rapidly progressing to TB disease (e.g., contacts in daycare, HIV care-settings, and dialysis centers)
- Resources available (ask for help, if necessary, e.g., State TB Control or LHD epi team, immunization team, STD team)


^{*} transmission is still possible for cases with negative sputum smears

Smear Result (Number of AFB observed at 1000X magnification)	Smear Interpretation	Infectiousness of Patient	
4+ (>9/field)	Strongly positive	Probably very infectious	
3+ (1-9/field)	Strongly positive	Probably very infectious	
2+ (1-9/10 fields)	Moderately positive	Probably infectious	
1+ (1-9/100 fields)	Moderately positive	Probably infectious	
+/- (1-2/300 fields)*	Weakly positive [†]	Probably infectious	
No acid-fast bacilli seen	Negative	Probably not infectious**	

Smear Classification Results

Higher Smear = Higher Risk

11



Questions Needing Answers

First questions needing answers through medical records review and initial interview:

- •Is my patient contagious?
- •How do I know if my patient is contagious?
- •If my patient is contagious, how contagious is he/she?
- •How do I know when my patient first became contagious?
- •How do I know how long my patient has been contagious?

13

Determining Infectiousness

Clinically


- Site of disease (typically pulmonary, pleural or laryngeal)
- Symptoms (fever, cough, hemoptysis, night sweats, weight loss)

Radiologically

Abnormal CXR (cavities, infiltrates, ground-glass opacities, lymphadenopathy)

Microbiologically

Positive sputum (AFB smears, NAAT/PCR, culture)






What is the Infectious Period?


Time during which TB case is likely to transmit TB.

Why is determining infectious period so important?

- •Focuses investigation on contacts most likely to be at risk of infection.
- Identifies timeframe for testing contacts (i.e., when repeat TST or IGRA is due).


_	Recommendations for Estimating the Start of Characteristic of Case Respiratory TB Sputum Smear Pulmonary Cavity on Chest X-ray		Recommended Minimum Beginning of the Infectious Period	Estimating Start of Infectious	
	Yes	No	No	3 months before symptom onset or first finding consistent with TB disease, whichever is longer	Period
	Yes	Yes	Yes	3 months before symptom onset or first finding consistent with TB disease, whichever is longer	3 months before 1 st respiratory symptom or 1 st diagnostic finding
	No	No	No	1 month (4 weeks) before date of suspected diagnosis	If smear negative,
	No	Yes	Yes	3 months before finding consistent with TB disease	asymptomatic (non cavitary): 1 month





	A. Criteria		ing of the Infectious Period	C. Infectious Period Star
TB Symptoms	Acid Fast Bacilli (AFB) Sputum Smear Positive	Cavitary CXR	B. Estimated Start of Infectious Period Select any of the following based on criteria met by client in Column A	Select <u>earliest</u> date of sympton onset listed in Table 1
Yes	Yes	Yes	Three (3) months before symptom onset or first positive finding consistent with TB disease (e.g. abnormal chest radiograph) whichever is longer.	
Yes	Yes	No		
Yes	No	No		
No	Yes	Yes	Three (3) months before first positive finding consistent with TB	
No	No	No	Four (4) weeks before date of suspected diagnosis	

	A. Criteria	B. Check (√) when criteria is met	C. Infectious Period End Date Type the date the selected criteria in Column A was met
	Three (3) consecutive negative AFB sputum smears, collected in 8 to 24 hour intervals (one should be an early morning specimen)		
When patient has POSITIVE AFB sputum smear at diagnosis	Symptomatic improvement Effective multi-drug therapy for tuberculosis for at least the equivalent of two weeks given as directly observed therapy (DOT)		
	Completely adherent with DOT Drug resistance is not suspected or confirmed		
When patient has three consecutive	Three (3) consecutive negative AFB sputum smears, collected in 8 to 24 hour intervals (one should be an early morning specimen) Symptomatic improvement		
NEGATIVE AFB sputum smears at diagnosis <u>and</u> has never had a positive sputum specimen	Multi-drug therapy for tuberculosis for at least 5 days given as DOT		
	Completely adherent with DOT Drug resistance is not suspected or confirmed		-



Environmental Factors to Disease Transmission

ENVIRONMENTAL	LIKELIHOOD OF DISEASE TRANSMISSION			
FACTOR	HIGH	LOW		
Volume of shared air space	Low (small)	High (large)		
Adequacy of ventilation	Poor	Good		
Re-circularized air	Yes	No		
Upper room ultraviolet light	Not present	Present		


www.cdc.gov/tb/education/corecurr/pdf/chapter2.pdf

23

Reflection

- •We determined when a TB contact investigation should or should not be initiated.
- •We learned how to prioritize contact investigations.
- •We reviewed how the infectiousness of a TB case, and the calculation of the infectious period is crucial to identifying contacts.
- •A thoughtful and systematic approach are required for successful contact investigations.





References

Centers for Disease Control and Prevention. (2021). Core curriculum on Tuberculosis: What the clinician should know, 7th ed. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from https://www.cdc.gov/tb/education/corecurr/pdf/CoreCurriculumTB-508.pdf

Centers for Disease Control and Prevention. Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC, United States. MMWR 2005a; 54 (No. RR-15). Retrieved from https://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf

Nahid, P., Dorman, S.E., Alipanah, N., Barry, P.M., Brozek, J.L., Cattamanchi, A., Chaisson, L.H., Chaisson, R.E., Daley, C.L., Grzemska, M., Higashi, J.M., Ho, C.S., Hopewell, P.C., Keshavjee, S.A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., Peloquin, C.A., Raftery, A., Saukkonen, J., Schaaf, H.S., Sotgiu, G., Starke, J.R., Migliori, G.B., Vernon, A.; Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63 (7): 853-867. doi: 10.1093/cid/ciw566

Centers for Disease Control and Prevention. (2016). Targeted Tuberculosis (TB) Testing and Treatment of Latent TB Infection. PowerPoint file. Retrieved from https://www.cdc.gov/tb/publications/slidesets/ltbi/ltbi.pptx